The downregulation of TRAF3IP2-AS1 resulted in reduced PTEN expression, facilitating the progression of NONO-TFE3 tRCC by inducing the m6A modification of PARP1 mRNA. This evidence concerns the gene TFE3 and renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.